Research and Markets: Global Postmenopausal Vaginal Atrophy Drug Forecast and Market Analysis to 2022
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bdvvpr/pharmapoint) has announced the addition of the "PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022" report to their offering.
“PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022”
New Postmenopausal Vaginal Atrophy Therapeutics to Provide Boost for Market Growth and Female Libido
The Postmenopausal Vaginal Atrophy (PVA) therapeutics market will double from $1 billion to approximately $2 billion over the next decade, with the US being the largest global contributor, according to a new report from research and consulting firm The authors.
Between 2012 and 2022, the global PVA therapeutics market will grow at a Compound Annual Growth Rate (CAGR) of 6%. This will be backed significantly by the US market, which will climb from $976 million to $1.9 billion over the 10-year period, at a CAGR of 6.3%.
Combined, the UK, France, Germany, Italy and Spain are expected to follow with a PVA therapeutics market revenue of $149 million in 2022, while the Japanese market will reach a value of $20 million by the same year.
The launch of Shionogi's Osphena, which is a treatment for the large number of women suffering from dyspareunia, a prevalent symptom of PVA, is expected to be a significant market-driving force across these seven major markets in 2013.
Meanwhile, Vaginorm could well dominate the global PVA market thanks to its potential of being black box warning-free, as well as its claims of helping to bolster female libido.
Anita Angelica Moore, Therapy Analyst covering Oncology and Women's Health, says: Although the PVA market has experienced anemic growth over the past decade, it is expected to undergo considerable changes spurred by the launch of these products by 2014.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Opportunity and Unmet Need
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- Novo Nordisk
- Bayer AG
For more information visit http://www.researchandmarkets.com/research/bdvvpr/pharmapoint